Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Brian Persing

Hematology | Oncology
Singing River Health System
2809 Denny Ave, 
Pascagoula, MS 
Offers Telehealth
Advanced in WT1-Related Wilms Tumor Syndromes
Singing River Health System
2809 Denny Ave, 
Pascagoula, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Persing is a Hematologist and an Oncologist in Pascagoula, Mississippi. Dr. Persing is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Adult Soft Tissue Sarcoma.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MS
Hospital Affiliations
Singing River Health System
Singing River Gulfport
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

SINGING RIVER HEALTH SYSTEM
2809 Denny Ave, Pascagoula, MS 39581

Additional Areas of Focus

Dr. Persing has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2024
Intervention Type: Drug
Study Drugs: Efineptakin alfa, Atezolizumab
Study Phase: Phase 2
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
View 2 Less Clinical Trials

1 Total Publications

Using Federal, State, and Grassroots Advocacy to Effect Change in Cancer Care Delivery and Patient Outcomes in the United States.
Using Federal, State, and Grassroots Advocacy to Effect Change in Cancer Care Delivery and Patient Outcomes in the United States.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 23, 2024
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Allison P. Wall
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Allison P. Wall
Hematology Oncology | Hematology | Oncology

Memorial Hospital At Gulfport

4500 13th St, 
Gulfport, MS 
 (34.7 miles away)
228-867-3152
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Allison Wall is a Hematologist Oncology specialist and a Hematologist in Gulfport, Mississippi. Dr. Wall is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Appendix Cancer, Hemangioma Thrombocytopenia Syndrome, Paget Disease of the Breast, and Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). Dr. Wall is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Brian J. Heller
Hematology Oncology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Brian J. Heller
Hematology Oncology | Oncology

Southern Cancer Center PC

1703 N Bunner St, 
Foley, AL 
 (50.7 miles away)
251-625-6896
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brian Heller is a Hematologist Oncology specialist and an Oncologist in Foley, Alabama. Dr. Heller is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Breast Cancer. Dr. Heller is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Sherri Arledge
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Sherri Arledge
Hematology | Oncology

Southern Cancer Center PC

3719 Dauphin St, Suite 5, 
Mobile, AL 
 (32.1 miles away)
251-625-6896
Languages Spoken:
English
See accepted insurances

Sherri Arledge is a Hematologist and an Oncologist in Mobile, Alabama. Dr. Arledge is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Thrombocytopenia, Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Persing's expertise for a condition
ConditionClose
    View All 49 Advanced Conditions
    View All 122 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile